PRMT5 and neuroblastoma: These findings were corroborated across another independently verified and annotated set of neuroblastoma biopsies (SEQC; n = 498 patients) [36] where in a similar way to the other biopsy collection, high PRMT5 and E2F1 coincided with MYCN expression, occurred in stage 4 disease and correlated with poor overall survival (Fig. S1C,D).